Abstract:OBJECTIVE:Pulmonary hypertension is a proliferative vascular disease characterized by pulmonary vascular structural remodeling. Until now, the pathogenesis of pulmonary hypertension is still not fully understood. Although considerable progress has been made, there is, to date, no cure for advanced pulmonary vascular disease. Recently, a number of studies suggest that endogenous vascular elastase (EVE) play a role in the vascular changes associated with pulmonary hypertension. The purpose of the study was to determine whether an elastase inhibitor might reverse advanced pulmonary vascular disease produced in rats by injection of monocrotaline.METHODS:One hundred and twenty male Sprague-Dawley rats were used in this study. The rats were divided into three groups: control, model and ZD-0892 groups. In the model and ZD-0892 groups, the rats were subjected to a single subcutaneous injection of monocrotaline (60 mg/kg) in the hind flank, while the rats in control group received an equivalent volume of 0.9% saline. From day 21, the rats in the ZD-0892 and model groups received twice-daily gavage tube feedings of either ZD-0892 at a dose of 240 mg/kg per day or its administration vehicle, while the rats in control group were subjected to an equivalent volume of 0.9% saline. On days 21, 28 and 35 post-injection, the elastolytic activity was measured with a fluorescence microplate reader and pulmonary artery pressure was detected via catheterization. Meanwhile, the lungs were evaluated morphologically, using the barium-gelatin perfusion technique.RESULTS:The injection of monocrotaline led to severe pulmonary hypertension in rats 21 days later and pulmonary artery elastolytic activity increased remarkably. A 1-week treatment with ZD-0892 resulted in declines in elastase activity. This was associated with significant declines in pulmonary artery pressure, decreases in muscularization of peripheral arteries and reductions in medial hypertrophy. After 2 weeks, elastase activity returned to normal level. Pulmonary artery pressure and structure were normalized.CONCLUSION:Increased elastase activity is important in the development of vascular changes and progressive pulmonary hypertension. ZD-0892 can suppress the elastase activity and completely reverse the fatal pulmonary hypertension induced by monocrotaline in rats.

Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism.

Rosuvastatin Reverses Hypertension-Induced Changes in the Aorta Structure and Endothelium-Dependent Relaxation in Rats Through Suppression of Apoptosis and Inflammation.

Effects of Rosiglitazone on Serum Levels of Lipids and Inflammatory Factors in Atherosclerotic Rats

Rosuvastatin-attenuated heart failure in aged spontaneously hypertensive rats via PKCα/β2 signal pathway.

Involvement of asymmetric dimethylarginine and Rho kinase in the vascular remodeling in monocrotaline-induced pulmonary hypertension.

Ethyl pyruvate ameliorates monocrotaline-induced pulmonary arterial hypertension in rats.

L-arginine restores endothelial nitric oxide synthase-coupled activity and attenuates monocrotaline-induced pulmonary artery hypertension in rats.

Simvastatin protects against the development of monocrotaline-induced pulmonary hypertension in rats via a heme oxygenase-1–dependent pathway

Activation of Peroxisome Proliferator-Activated Receptor Γ Ameliorates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats

The effects of aspirin on monocrotaline-induced pulmonary arterial hypertension in rats

All-TRANS RETINOIC ACID INTERFERES DEVELOPMENT OF PULMONARY HYPERTENSION INDUCED BY MONOCROTALINE IN RATS

Betaine Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats via Inhibiting Inflammatory Response

Genistein, Bosentan and Tadalafil in Treatment of Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats: a Comparison of Efficacy

Protective effects of aloperine on monocrotaline-induced pulmonary hypertension in rats.

Rosuvastatin Attenuates the Elevation in Blood Pressure Induced by Overexpression of Human C-reactive Protein

Rosmarinic acid ameliorates the complications of monocrotaline-induced right ventricular hypertrophy on the left ventricle: Investigating the signaling pathway of Wnt/β-catenin in the heart

Effects of Ang-(1-7) on Pulmonary Hypertension and Right Ventricular Remodeling in Monocrotaline-Treated Rats

[Effect of Elastase Inhibitor on Pulmonary Hypertension Induced by Monocrotaline].

Atorvastatin Prevents Dehydromonocrotaline-Induced Pulmonary Hypertension in Beagles.

Hydroxycitric Acid Tripotassium Hydrate Attenuates Monocrotaline and Hypoxia-Induced Pulmonary Hypertension in Rats

Inhibition of Ubiquitin Proteasome Function Prevents Monocrotaline-Induced Pulmonary Arterial Remodeling